A focus on the use of artificial intelligence to personalize blood cancer care
Sep 30, 2024
auto_awesome
Join Carsten Niemann, a leading hematological oncologist from Copenhagen University Hospital, as he delves into the transformative power of artificial intelligence in personalizing blood cancer care. Discover how AI enhances treatment for Chronic Lymphocytic Leukemia by predicting individual risks and improving decision-making. Niemann discusses a novel treatment infection model his team developed, while Gareth Morgan from NYU Langone highlights AI's role in classifying multiple myeloma patients and its potential to predict transplantation needs.
Artificial intelligence is revolutionizing blood cancer treatment by personalizing care through models like the CLL treatment infection model using 80 key variables.
The integration of AI with electronic health records enhances clinical decision-making by providing real-time support and optimizing patient management for myeloma and CLL.
Deep dives
The Role of Artificial Intelligence in Personalized Treatment
Artificial intelligence (AI) is transforming the management of blood cancer by personalizing treatment based on individual patient data. One notable application is a treatment infection model for chronic lymphocytic leukemia (CLL) developed at Copenhagen University Hospital, which uses machine learning to analyze various data points to predict patients' risk of severe infections. The model incorporates 80 key variables, simplifying decision-making for healthcare providers. By identifying specific risk factors tied to individual patients, this approach fosters tailored treatment plans rather than relying solely on generalized risk assessments.
Integrating AI into Clinical Practices
The integration of AI into clinical workflows is a significant step toward enhancing patient care in hematology. By deploying AI within electronic health records (EHR), healthcare providers can receive real-time decision support, thus improving patient management and treatment outcomes. A specific example includes the efforts made to integrate an open-source CLL treatment infection model into Denmark's EHR system, ensuring that predictions based on vast patient data are accessible for practical use in clinical environments. This integration not only supports clinicians in making informed decisions but also paves the way for ongoing monitoring and adjustments based on patient responses.
AI's Impact on Myeloma Treatment Decisions
AI is being harnessed to refine the classification of myeloma patients and predict their need for treatments like autologous stem cell transplantation. Utilizing data from thousands of patients, researchers have been able to create classifiers that effectively distinguish which patients may benefit from aggressive treatments versus those who can maintain long-term remission with less intensive therapies. This capability minimizes unnecessary exposure to the side effects of intensive treatments while optimizing care. Additionally, advancements in genomic data analysis are anticipated to further enhance clinical insights, potentially leading to even more personalized treatment protocols.
Welcome to the final episode of VJHemOnc’s Blood Cancer Awareness Month special series!
This episode focuses on the role of artificial intelligence (AI) in personalizing blood cancer care. Carsten Niemann, MD, PhD, Copenhagen University Hospital, Copenhagen, Denmark, discusses the value of AI in hematological oncology and how it is currently used in the clinic. He then shares details of a treatment infection model for chronic lymphocytic leukemia (CLL) that has been deployed in his institution. Gareth Morgan, MD, PhD, FRCP, FRCPath, NYU Langone, New York City, NY, delves into the role of AI in the classification of multiple myeloma and the prediction of patients who will need transplantation. He also touches on the use of AI to better understand genomic data.